Our Movers, Thinkers & Doers

Strategic Advisory Team
Becky Oberle, Ph.D.
+
Becky Oberle Ph.D.

Becky is our patient focused advisor.  When Becky’s father, Jim, was diagnosed with acute myeloid leukemia in 2011, she learned the lack of investment in safe and transformative therapies and redirected her energy to help identify and develop transformative therapies.

Becky has held scientific management positions in the area of preclinical research and development at the Upjohn Company, Ciba-Geigy, Novartis, Johnson & Johnson and Hurley Consulting Associates.

Becky has a Bachelor of Arts degree in chemistry from the College of Wooster and a Ph.D in pharmaceutical chemistry from the University of Michigan.

Mohan Iyer, M.S., M.B.A.
+
Mohan Iyer M.S., M.B.A.

Mohan is our independent Board of Director. He is currently serving as the Chief Operating Officer at Whole Biome, a leading start- up in the microbiome field.  He started his career as a biochemical engineer at Genentech in the mid-80s, when the biotech industry itself was comprised of start-ups.

In a career spanning over 30 years in biotech, he has held various executive level positions at several venture capital funded start-ups in the San Francisco Bay Area including diaDexus, Tethys, and Second Genome.

 He also serves on a variety of advisory boards. Mohan has a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke), and an MBA (Yale).

Laura O. Spiegleman, J.D.
+
Henry Lau, Ph.D

Laura is a Founder/Partner of Spiegelman Life Sciences PC and has more than 20 years of legal experience focused exclusively on life sciences IP-related transactions.  

She was also a founding member of a group at Morrison & Foerster that focused on investor-side IP due diligences of life sciences companies.

Laura gained critical operating experience as a general counsel at Kosan Biosciences and also had a life sciences transactions practice in Cooley-Godward.  

She is a member of the Licensing Executives Society (LES) and has served as Board Member/Secretary of the Professional Women’s Healthcare Alliance, an independent Bay Area industry group for women in the biotechnology and medical device industries.

Laura received her received her B.A., cum laude, in Biology and French from Amherst College and J.D., Order of the Coif, With Distinction from Stanford Law School.

Nigel Flemming, Ph.D.
+
Harish Vasudevan Ph.D.

Nigel is a serial entrepreneur with 25 years of experience in biotechology.  He is currently serving as the President and CEO of G2B Pharma, Inc.  Prior to G2B, he was the founder and chairman of Athena Diagnostics a neurological diagnostics company which recently was valued at $740m.

He continues to serve on the board of Impax Laboratories (ipxl) a publically traded pharmaceutical company. He has also consulted and served in various leadership roles at a number of early-stage biotechnology companies, including Gamera Biosciences, Neurocal, Nephros, TheraMed Partners and Plant Cell Technologies.  He served as Chairman of Minoryx Therapeutics, Director of Genmedica Therapeutics S.L. and A-CUBE, Inc. He served as a Board Director for the Institute for OneWorld Health and Impax Laboratories Inc.

Nigel holds a BS from the University of North Carolina at Chapel Hill as a Morehead Scholar and holds a PhD from Cambridge University and completed his post doc at Harvard University.

Ulrich Muehlner, Ph.D.
+
Vani Velamoor Ph.D.


Ulrich is our digital strategy expert.  Ulrich was at Novartis and held global roles of increasing responsibilities.  He joined Novartis as Director of Corporate Strategy and led the annual group-wide strategic planning process as well as key initiatives in areas such as emerging markets, digital health, innovation driven growth opportunities, and novel R&D approaches.

Subsequently, as the Global Head Corporate Strategy, he led the development of the portfolio strategy resulting in the fundamental transformation of the Novartis business portfolio through multibillion dollar asset deals.  He also led and managed Novartis LP investments into two China healthcare VC funds.  Ulrich was the Global Head at Outcomes Technologies Incubator (NOVAE) at Novartis.

Ulrich studied Biochemistry in Hannover and Munich, and earned a Ph.D. degree in Biochemistry and Molecular Biology at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.  He currently serves as board member of E-Medicus and Medicinisto.

Sign Up for EpiDestiny Updates